Skip to main content
. 2021 May 18;13(10):2458. doi: 10.3390/cancers13102458

Figure 2.

Figure 2

Mutation status has prognostic significance for overall survival and relapse-free survival. In the global series, the AZA arm’s and FLUGA arm’s overall survival and disease free-survival are represented by Kaplan–Meier plots. Wild-type status is indicated in blue and mutated status is indicated in red. NRAS mutations (a) and TP53 mutations (b) are adverse factors affecting overall survival in the FLUGA arm. BCOR mutations are adverse factors affecting relapse-free survival in the AZA and FLUGA arms (c). AZA: azacytidine, FLUGA: fludarabine plus low-dose cytarabine (LDAC).